Title:
免疫因子を指標とした肺腺癌の予後演算式作成方法と予後推定方法
Document Type and Number:
Japanese Patent JP6675716
Kind Code:
B2
Abstract:
Provided are a method for more easily and quickly predicting the prognosis in lung adenocarcinoma, and a method for creating a computing equation for embodying the aforesaid method. The method according to the present invention for creating an equation for computing prognosis is characterized by comprising: detecting the expression of PD-L1, Gal-9 and XAGE1 in specimens obtained from a plurality of lung adenocarcinoma patients using an immunostaining technique; on the basis of first data, said first data being obtained by binarizing a first score that is specified on the basis of the distribution range and expression intensity of PD-L1 of tumor in a tumor tissue, second data, said second data being obtained by binarizing a second score that is specified on the basis of the distribution range and expression intensity of Gal-9 of tumor in a tumor tissue, and third data, said third data being obtained by binarizing on the basis of the presence or absence of XAGE1 expression, dividing the lung adenocarcinoma patients into a good-prognosis cluster and a poor-prognosis cluster; and determining the computing equation for dividing the good-prognosis cluster and the poor-prognosis cluster by multivariate analysis using the first score, second score and third data as explanatory variables. The method according to the present invention for predicting the prognosis in lung adenocarcinoma is characterized by comprising substituting first and second scores and third data detected from a specimen of a subject into the computing equation determined above and predicting the prognosis of the subject by computation.
Inventors:
Yoshihiro Ohue
Mikio Oka
Hiroshi Kurose
Nakayama Mutsumi
Mikio Oka
Hiroshi Kurose
Nakayama Mutsumi
Application Number:
JP2017517920A
Publication Date:
April 01, 2020
Filing Date:
May 06, 2016
Export Citation:
Assignee:
Kawasaki Gakuen
International Classes:
G01N33/574; G01N33/48; G01N33/53
Domestic Patent References:
| JP2012515334A | ||||
| JP2014158500A |
Other References:
大植祥弘,非小細胞肺癌患者におけるXAGE-1b(GAGED2a)に対する宿主免疫応答の解析,川崎医学会誌,2011年,37(4),223-232
SCHULKENS, A. Iris et al.,Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Δ5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer,PLOS ONE,2014年 9月26日,9(9): e107988,1-9
WAKI, Kayoko et al.,PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer,Cancer Science,2014年10月,105(10),1229-1235
U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer,Media Release,F. Hoffmann-La Roche Ltd.,2015年 2月 2日,URL,http://www.roche.com/med-cor-2015-02-02-e.html
SCHULKENS, A. Iris et al.,Galectin Expression Profiling Identifies Galectin-1 and Galectin-9Δ5 as Prognostic Factors in Stage I/II Non-Small Cell Lung Cancer,PLOS ONE,2014年 9月26日,9(9): e107988,1-9
WAKI, Kayoko et al.,PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer,Cancer Science,2014年10月,105(10),1229-1235
U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer,Media Release,F. Hoffmann-La Roche Ltd.,2015年 2月 2日,URL,http://www.roche.com/med-cor-2015-02-02-e.html
Attorney, Agent or Firm:
Takashima Ichi
Kyoko Doi
Mitsunori Kamata
Yaeko Tamura
Junzo Koike
Hirofumi Toma
Atsuko Akai
Tomiya Tozaki
Kyoko Doi
Mitsunori Kamata
Yaeko Tamura
Junzo Koike
Hirofumi Toma
Atsuko Akai
Tomiya Tozaki